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Contact hypersensitivity  (CH)  to simple haptens and acute allograft  rejection are 
generally  regarded  as  T  cell-mediated  responses.  However,  at  the  present  time, 
considerable controversy exists concerning the precise phenotype of the effector cells 
that  are  the proximate causes of inflammation  and  tissue destruction.  In transplan- 
tation  immunity,  the  assumption  of a  decade  ago--that  cytotoxic T  lymphocytes, 
predominately of the Lyt-1-23  + type, are the mediators of acute allograft rejection-- 
has been strongly challenged by recent data identifying the T  cell subpopulation that 
mediates  delayed-type hypersensitivity reactions  (TD-rn, Lyt-l+23  -)  as an equally  (if 
not more so)  important  participant  in specific graft destruction  (1,  2).  Similarly,  the 
general belief that TDTH cells mediate contact hypersensitivity (3) has been challenged 
by Tagart  (4)  and more recently by Sunday and Dorf (5), who have demonstrated  a 
role for cytotoxic T  cells in the deve!opment of CH reactions in the skin. In this time 
of controversy, our laboratory has been involved in the study of both transplantation 
immunity and contact hypersensitivity and  it  seemed that  useful information might 
emerge  from experiments  designed to study both  types of cell-mediated  immunities 
simultaneously.  The experiments  and results  to be described examine the possibility 
that hapten-derived skin grafts can serve as the targets of an immune response elicited 
by typical contact hypersensitivity-inducing regimens. 
Materials  and Methods 
Mice.  Adult mice,  ages 8-16 wk,  of the following strains  were used:  C57BL/6,  BALB/c, 
C57BL/10 (B 10)-H-2 b, B20.M-H-2  f. These mice, as well as the (B10 X B10.M)F~ hybrid, were 
produced in our animal facility. 
Contact  Hypersensitivity.  Immunization  to  the  haptens  dinitrofluorobenzene  (DNFB)  and 
oxazalone  was  achieved  as  described  previously  (6). Briefly,  25  /,tl of 0.5%  DNFB  (or  5% 
oxazalone)  in  carrier  (4:1  acetone/olive  oil)  was  applied  on  days  0  and  1 to  dry-shaved 
abdominal skin of recipient mice. 
Skin Grafting.  Skin grafts from clipped body wall skin were prepared as described previously 
(7). Full thickness grafts were placed on thoracic wall beds and wrapped with plaster of paris 
bandages. Bandages were removed 8 d later.  Graft rejection was assessed by visual  inspection. 
Rejection was determined when all evidence of surface epidermis had disappeared. 
Hapten  Derivatization  of Skin  Grafts.  In some experiments,  skin  to be used  in  grafting was 
shaved in the manner for hapten sensitization and 0.2% DNFB in carrier applied  1-2 h before 
excision.  Grafts were  fashioned  from this  skin  in  the typical  manner.  In other experiments, 
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grafts in residence on the thoracic wall were painted with 0.2% DNFB (or 1% oxazalone) in 20 
~1 of carrier, and their subsequent survival was observed. 
Neonatal Transplantation Tolerance.  Tolerance  to  alloantigens  of the  H-2b haplotype  was 
induced in neonatal BI0.M mice by intravenous inoculation of (B10 ×  B10.M)F1 spleen  and 
bone marrow cells as described  previously (7). At 8 wk of age these mice received  orthotopic 
B 10 skin grafts.  Mice accepting their grafts in excess of 60 d were considered to be tolerant. 
Results 
Toxicity of DNFB for Orthotopically Grafted Skin.  DNFB,  a  hapten  used  widely  for 
study of contact hypersensitivity, is toxic to the skin in a  dose-related fashion when 
painted epicutaneously. Our first experiments defined a dose range of DNFB that was 
suitable for the grafting studies we planned to conduct.  Dry-shaved abdominal skin 
of BALB/c mice was painted with 0.2%, 0.5%, 2.0%, and 5% DNFB in carrier (50 ttl 
covering an area 2.5 cm diam).  1 h  later the donors were killed, and skin grafts were 
prepared in conventional fashion. These grafts were then placed on beds prepared on 
the thoracic cage of syngeneic, normal recipient mice. Plaster of paris bandages were 
applied  for protection.  8  d  later the  casts were  removed and  the  grafts inspected. 
Grafts painted with 2 and 5% DNFB proved to be nonviable and were sloughed from 
their beds. A few of the grafts painted with 0.5% DNFB suffered severe inflammatory 
reactions,  although  all eventually healed  in  place. Grafts painted  with 0.2% DNFB 
were  stained  light  yellow  and  displayed  a  mild  inflammatory  response of similar 
intensity to that observed in unpainted syngeneic grafts examined at a  similar time 
after grafting. Grafts painted with 0.2% DNFB healed in perfectly at the graft site. By 
14  d,  all  evidence  of  yellow  staining  had  disappeared  by  gross  inspection.  For 
subsequent experiments, the 0.2% DNFB dose was used routinely to derivatize skin to 
be used in grafting studies. 
Susceptibility of Hapten-derivatized Skin  Grafts to Acute Rejection in Hapten-immune Recipi- 
ents. In the first experiments, skin grafts were prepared from normal abdominal wall 
skin of C57BL/6 and BALB/c mice, and placed on thoracic walls of syngeneic mice. 
On the following day, the abdomens of the graft-bearing mice were dry-shaved and 
painted  with  0.5%  DNFB.  Control  panels of grafted mice were painted  with  10% 
oxazalone.  These epicutaneous paintings were repeated on the subsequent  day. On 
the 8th  d  after grafting, the plaster bandages were removed. On  the next day (9  d 
after grafting) the surface of the grafts was painted with 0.2% DNFB in carrier. Care 
was taken to avoid spread of the hapten solution across the margins of the graft on to 
body wall skin. The surface of these grafts was observed by gross inspection over the 
next  several  days.  DNFB-painted  grafts  on  DNFB-immune  recipients  developed 
intense  inflammatory reactions within  24  h  (see Table I). This inflammatory crisis 
became particularly acute at 48 h, at which  time mild stroking of the graft surface 
with a fine forceps easily dislodged the epidermal covering, exposing raw dermis. On 
C57BL/6  mice, the majority of DNFB-derivatized grafts were destroyed.  Similarly, 
among DNFB-immune BALB/c mice, six of nine grafts were destroyed (rejected). In 
grafts  that  were  not  destroyed  within  72  h  of hapten  painting,  the  inflammatory 
reaction  gradually  subsided  and  these  grafts  healed  in  place.  Several  grafts  were 
shrunken  in  size  and  none  grew  fresh  crops  of  fur  during  the  subsequent  30-d 
observation period. By contrast,  DNFB-painted grafts on oxazalone-immune recipi- 
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TABLE  I 
Survival  of DNFB-derivatized Skin Grafts on Hapten-immune  Recipient  Mice 
Number  Number  Number 
Straiil  Immune to  grafted  wilh crises  rejected 
C57BI./6  DNFB  I0  10  8 
Oxazal~me  9  0  0 
BALB/6  DNFB  9  9  6 
()xazalone  10  (}  0 
0.9~  DNFB was applied  to skin graft 9 d  after graft was placed on thoracic wall. 
reactions  promptly subsided  and  even  vigorous stroking  of the  graft  surface  with 
forceps  failed  to  separate  the  epidermis  from dermis.  All  of these  grafts  healed  in 
place and the majority demonstrated  new fur growth during the subsequent  obser- 
vation period.  Thus,  it would  appear that  hapten-immune  animals can respond  to 
syngeneic skin grafts that have been derivatized with the same hapten by mounting 
an immunologically specific inflammatory response that is deleterious to the graft. 
We next investigated whether the time interval between grafting and application 
of hapten was crucial to the rejection process. Panels of C57BL/6 mice were grafted 
orthotopically with normal, syngeneic abdominal skin.  Their plaster bandages were 
removed 8 d later. On day 21 after grafting, the abdominal skin of these animals was 
shaved and  painted  with  an  immunogenic  dose of DNFB.  This was repeated  24  h 
later. On the 27th d after grafting, 0.2% DNFB in carrier was applied carefully to the 
surface of the grafts. As observed by gross inspection, these healed-in grafts developed 
mild inflammatory changes during the subsequent  24 h, but the response was neither 
intense nor sustained.  In no instance were these grafts rejected.  Thus, the ability of 
hapten-immune mice to reject syngeneic skin grafts painted with hapten is dependent 
upon the time interval that elapses between grafting and challenge of the graft with 
hapten. We presume, but have no direct evidence, that the vulnerability of fresh skin 
grafts to hapten-specific rejection relates to the healing-in process itself. 
In an effort to procure rejection  of all rather  than  only some hapten-derivatized 
grafts in this experimental system, we explored two additional protocols. In the first, 
0.2% DNFB was painted on the shaved abdominal skin of donor C57BL/6 mice  1 h 
before killing.  Grafts were prepared from these donors and placed orthotopically on 
syngeneic recipients.  These  animals were  immunized  to  DNFB  by abdominal  skin 
painting over the  next  2  d.  When  the  protective dressings  were removed on  day 8 
after grafting, the survival of the grafts was observed. As the data in Table II indicate, 
~50% of these grafts were rejected.  By contrast, no DNFB-derivatized grafts placed 
on oxazalone-immunized mice were rejected. 
In  the  second  approach,  DNFB-derivatized  grafts  were  placed  on  syngeneic 
BALB/c recipients who were immunized  to DNFB  1 and  2 d  later.  The protective 
dressings were removed on day 8 after grafting; the grafts were once again challenged 
with  0.2%  DNFB  24  h  later.  All  of these  grafts  developed  intense,  inflammatory 
reactions and all succumbed to this process within 48 h  of the second painting with 
hapten  (data presented  in Table II). Control  mice received DNFB-derivatized skin 
grafts but were not immunized on their abdominal skin with the hapten.  However, 
when  their  grafts were rechallenged  with  0.2%  DNFB  after removal of the  plaster 
casts, 50% of these grafts developed severe inflammation and two were rejected. We 
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TABLE  II 
Influence of Time of DNFB Application on Survival of Syngeneic Skin Grafts on DNFB-immune Mice 
Number 
Immune status of recipients  Time of DNFB application to syngeneic skin  Number  with cri-  Number 
grafts*  grafted  sis  rejected 
C57BL/6 immune to DNFB  Before graft preparation  20  12  11 
C57BL/6 normal  Same as above (control)  9  0  0 
BALB/c immune to DNFB  Before graft preparation and 9 d  later  9  9  9 
BALB/c normal  Same as above (control)  10  5  2 
* DNFB painted at concentration of 0.2% in carrier. 
TABLE  III 
Evidence of H-2 Restriction of Effector Cells Responsible  for Hapten-spec~'c 
Graft Rejection 
Donor of test  Number  Number  Number 
DNFB-immune recipients  graft*  grafted  with crisis  rejected 
B10.M  BI0.M  8  8  7 
B10.M tolerant of B10  B10  6  0  0 
* DNFB was applied to test grafts 9 d  after grafting. 
DNFB are capable in their own right of inducing typical contact hypersensitivity in 
recipient mice, and we presumed that this accounts for the "inappropriate" rejection 
of some control grafts in this experiment. 
H-2 Restriction  of Effector  Cells Mediating Hapten-specific  Graft Rejection.  The availa- 
bility of this assay system made it possible to design an experiment to test whether the 
cells that effect contact hypersensitivity are restricted in vivo by the products of H-2. 
B10.M  mice were rendered tolerant at birth by intravenous inoculation  of 15 ×  106 
(B10  ×  B10.M)F1  lymphohematopoietic cells.  At  8  wk of age,  these  animals were 
grafted with B 10 skin. Mice retaining their grafts beyond 60 d were regarded as fully 
tolerant.  B10.M  mice thus tolerant of B10 alloantigens received orthotopically fresh 
B 10 skin grafts. Control B 10.M mice received syngeneic B 10.M grafts. Both panels of 
mice were immunized to DNFB by abdominal skin painting  ! and 2 d after grafting. 
Their casts were removed on day 8 and the grafts were challenged with 0.2% DNFB 
the next day.  Every hapten-challenged  syngeneic B10.M  graft developed crisis  and 
seven  of eight  were  rejected  within  72  h  (see  Table  III). By contrast,  little  or  no 
inflammation was observed in the DNFB-painted (but tolerated) B 10 grafts and none 
were rejected. These results confirm that haptens when derivatized to skin can serve 
as surrogate transplantation  antigens  and dramatically address the in vivo require- 
ment for H-2 identity of effector cells and hapten-derivatized graft for the rejection 
response  to  be consummated.  Since  the  degree of hematopoietic chimerism  in  our 
tolerant mice is between 0.5  and  2%, the hapten-specific effector cells produced by 
skin painting are almost exclusively of B10.M  type (9).  Moreover, the vast majority 
of antigen-presenting cells are similarly of B10.M origin  (10). Thus, DNFB-specific, 
H-2 restricted  effector cells,  when  confronted  by DNFB  derivatized  H-2  b skin,  are 
unable to initiate an immunologically specific inflammatory reaction. 
Discussion 
To  our knowledge,  these  are  the  first  experiments  to  demonstrate  that  haptens, 
derivatized  to  intact  tissue  cells,  can  function  in  vivo as  transplantation  antigens. 13513  STREILEIN AND BERGSTRESSER  BRIEF  DEFINITIVE REPORT 
Contact hypersensitivity, induced  by conventional  methods, can express itself when 
hapten-immune mice are confronted by the hapten,  derivatized to syngeneic ortho- 
topic  skin  grafts.  The  expression  ranges  from  intense,  self-limited  inflammatory 
reactions within the grafted skin to outright destruction  (rejection) of the derivatized 
tissue.  This result  confirms that  the effector cell population  elicited  by exposure to 
sensitizing  haptens  includes  cells  capable  of  provoking  skin  graft  rejection.  We 
presume, but have no direct evidence, that these cells are typical DTH effectors. This 
conclusion would be concordant with an ever-increasing body of recent evidence that 
ascribes to TDTH cells a  predominant role in acute allograft rejection  (1), and would 
link the pathogenesis of contact hypersensitivity and acute transplantation  rejection 
by a common effector modality. 
The ability of hapten-immune recipients to reject syngeneic skin derivatized at the 
time of grafting is modest compared to their ability to reject grafts derived immediately 
after removal of protective dressings.  We suspect  that  this  difference  relates  to  the 
gradual  decay in  the  former group of cell surface hapten  concentration  during the 
time elapsed  after painting.  The fact that  syngeneic skin  grafts,  allowed  to heal  in 
place for 27  d  before derivation  with  DNFB,  were not  rejected  by DNFB-immune 
mice implies that the vulnerability of haptenated grafts is related in part to whether 
they  have  had  adequate  time  to  "heal"  in  place.  "Healing-in"  grafts  are  more 
susceptible  to  rejection  than  are  grafts  that  have been  in  residence  for prolonged 
intervals before induction of transplantation immunity (11-13). 
Perhaps the most interesting  finding to emerge from these studies  is that  DNFB- 
immune  mice,  rendered  H-2  tolerant  by  neonatal  inoculation  of  semiallogeneic 
hematopoietic cells, are incapable of rejecting hapten-derivatized skin grafts prepared 
from donors  bearing  the  tolerated  H-2 antigens.  It appears that  the TDTH effector 
cells,  induced  by abdominal  skin  painting  with  hapten,  recognized  the  hapten  in 
association  with  H-2  determinants  of  the  skin  (the  host)  and  are  subsequently 
restricted  in their ability to express DTH to tissues bearing the same H-2 antigens. 
Since  in  our  experiments  hapten-derivatized  grafts  bearing  only  "tolerated"  H-2 
determinants are not rejected, we conclude that the phenomenon of H-2 restriction of 
TDTH effector cells operates in vivo. This is more than a  trivial conclusion.  It is very 
difficult  to  devise  experimental  models  to  test  whether  the  phenomenon  of  H-2 
restriction operates in transplantation immunity. A recent publication from Silvers et 
al.  (14)  claims that rejection of minor H  incompatible skin and parathyroid grafts is 
H-2 restricted; these authors have taken advantage of the restricted tissue distribution 
of polymorphic minor histocompatibility antigens to test this possibility. In vivo H-2 
restriction  has also been demonstrated  in protection of mice against challenge with 
minor H-incompatible tumor cells (15)  and in the induction  of graft-vs.-host disease 
directed at minor H  antigens  (16).  Yet others have failed to find evidence of in vivo 
H-2 restriction in tissue transplantation  (17).  Resolution of this question is important 
since  minor immunogenetic disparity will  ultimately become important  in  clinical 
organ transplantation. 
Summary 
Hapten-immune  mice  are  capable  of  rejecting  syngeneic  skin  grafts  that  are 
derivatized with the relevant hapten, but only if the hapten is applied while the graft 
is "healing in." This model system was used to demonstrate that the hapten-specific STREILEIN AND BERGSTRESSER  BRIEF DEFINITIVE REPORT  1359 
immune effectors responsible for rejection are restricted by H-2 determinants of the 
recipient. Thus, haptens can be used in vivo as surrogate transplantation antigens for 
the study of immunopathogenic mechanisms in transplantation immunity. 
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